factually
Index/Organizations/GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)

GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)

Clinical trial

Fact-Checks

2 results
Jan 17, 2026
Most Viewed

How do GLP‑1 receptor agonists and SGLT‑2 inhibitors compare for cardiovascular and renal protection in type 2 diabetes?

Both GLP‑1 receptor agonists (GLP‑1 RAs) and SGLT‑2 inhibitors reduce cardiovascular and kidney risk in people with type 2 diabetes, but they do so with different strengths: GLP‑1 RAs show consistent ...

Jan 13, 2026
Most Viewed

What are the long‑term weight maintenance outcomes after stopping GLP‑1 therapy like semaglutide?

Clinical trials and systematic reviews consistently show that stopping GLP‑1 receptor agonists such as semaglutide is commonly followed by clinically meaningful weight regain — often returning a large...